Samarth Kulkarni

This profile gathers the share dealings of Samarth Kulkarni in CRISPR Therapeutics AG, where the filings describe the role as chief executive. Between 1 June 2021 and 14 October 2026, the trades on record add up to 53 filings.

The open-market record consists of 5 sales worth €4.1M, with no purchase. The rest of the record consists of 3 share grants and 42 option exercises. So far in 2026, the count stands at no purchases and 2 sales.

The record was last updated on 15 October 2026 with an option exercise in CRISPR Therapeutics AG. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.